Japanese drug firm Chugai Pharmaceutical has established competitive advantages due to its alliance with majority shareholder Roche as well as its internal research and development engine. While ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

Today's Research Daily features new research reports on 16 major stocks, including Roche Holding AG (RHHBY), Comcast Corp.

Sales of PBYI's sole-marketed drug, Nerlynx, exceeded management's expectations in fourth-quarter 2024. Also, ongoing studies on alisertib are progressing well.

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

The inquiry is the latest effort by the European Commission and European countries to scrutinize potential antitrust behavior ...

For the entire year, Phesgo increased (PDF) sales 62% to 1.74 billion Swiss francs (nearly $2 billion), Roche reported in late January. Herceptin sales fell 11% to 1.38 billion Swiss francs ($1.5 ...

Here's why La Roche-Posay is pulling its Effaclar Duo Acne Spot Treatment from retail shelves. La Roche-Posay is a brand under the L'Oreal Group umbrella. A La Roche-Posay spokesperson confirmed ...

The alleged excessive pricing of Trastuzumab by Roche took place in both the private and public healthcare sector in South Africa. Trastuzumab is a first line treatment life-saving drug which stops ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in ...